Should Congress reauthorize funding for the Patient-Centered Outcomes Research Institute (PCORI)? Professor William Padula writes the PCORI can generate research relevant for shifting to value-based healthcare.
This study provides the first evidence to our knowledge that near-universal access to Medicare at age 65 is associated with improvements in population-level cancer mortality, and provides new evidence on the differences in the impact of health insurance by gender.
In this letter published in JAMA Network Open, Neeraj Sood and Martha Ryan analyze recently enacted prescription drug pricing laws with a transparency component to determine which were informative and disclosed transaction prices.
166 recently enacted prescription drug pricing laws were analyzed to identify those that contained price transparency measures. Of these, 35 bills in 22 states include a transparency component, but only 7 were deemed to be informative.
States are increasingly enacting price transparency laws designed to provide regulators or the public with more information about how entities in the drug distribution system set prices. The data visualization summarizes the 35 drug pricing transparency bills enacted in states between 2015 and 2018.
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Patients change their behavior and the way they interact with the healthcare system in the face of an economic recession, and findings also suggest primary care providers changed their service intensity as a result of the recession.